Isolated stromal cells for use in the treatment of diseases of the central nervous system

• US 6,653,134 B2
• Filed: 02/24/1998
• Issued: 11/25/2003
• Est. Priority Date: 03/28/1995
• Status: Expired due to Fees

• Current Assignee: Allegheny University of The Health Sciences
• Original Assignee: CP Hahnemann University
• Inventors: Stokes, David G., Azizi, S. Ausim, Prockop, Darwin J.
• Primary Examiner(s): Siew, Jeffrey
• Assistant Examiner(s): SCHNIZER, RICHARD A
• Application Number:
  US09/028,395
• Publication Number:
  US 20030039639A1
• Time in Patent Office: 2,100 Days
• Field of Search: 435/455, 435/366, 435/368, 435/372, 435/373, 435/377, 424/93.21, 424/93.7, 424/570, 424/577
• US Class Current: 435/377
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/177 Receptors; Cell surface antigens; Cell surface determinants
• CPC Class Codes: A61K 38/2264 Obesity-gene products, e.g. leptin
• CPC Class Codes: A61K 38/44 Oxidoreductases (1)
• CPC Class Codes: A61K 38/4846 Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/4702 Regulators; Modulating activity
• CPC Class Codes: C07K 14/61 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: C07K 14/745 Blood coagulation or fibrinolysis factors
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• CPC Class Codes: C07K 16/2845 against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2502/08 : cells of the nervous system
• CPC Class Codes: C12N 2502/1311 : Osteocytes, osteoblasts, odontoblasts
• CPC Class Codes: C12N 2506/1353 : from bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 2799/027 : where the vector is derived from a retrovirus
• CPC Class Codes: C12N 5/0622 : Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
• CPC Class Codes: C12N 5/0663 : Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12Y 114/16002 : Tyrosine 3-monooxygenase (1.14.16.2)
• CPC Class Codes: C12Y 304/21022 : Coagulation factor IXa (3.4.21.22)

Abstract

Methods of treating a human patient having a disease, disorder or condition of the central nervous system are disclosed. The methods include obtaining a bone marrow sample from a human donor, isolating stromal cells from the bone marrow sample, and administering the isolated stromal cells to the central nervous system of the human patient, wherein the presence of the isolated stromal cells in the brain effects treatment of the disease, disorder or condition. Stromal cells which are isolated may be cultured in vitro, they may be genetically engineered to produce therapeutic compounds, and/or they may be pre-differentiated prior to administration into the central nervous system.

Claims

1. A method of directing the differentiation neural of an isolated stromal cell into a neural cell, comprising culturing said isolated stromal cell in the presence of a substantially homogeneous population of differentiated neural cells whereby said isolated stromal cell differentiates and acquires the phenotypic characteristics of said differentiated neural cells.

2. The method of claim 1, wherein said differentiated cells are astrocytes.